CHDI FOUNDATIONCHDI

Accelerating Therapeutic Development for Huntington's Disease

  • Preclinical research
  • Scientific Publications
  • Community Resources
    • Materials
      • Research tools & reagents
      • Mouse Models
      • Clinical biorepository
    • Data sharing & infomatics
      • Preclinical informatics: HDinHD
    • Funding & partnerships
      • Academic Proposals
      • External Partnership Proposals
    • HD expertise & guidance
      • Independent Statistical Standing Committee
      • Clinical outcomes: Rating scales
      • Field guide to HD mouse models
  • News & Video
    • News
    • HD Therapeutics Conference
      • 2023 Presentations
      • 2022 Presentations
      • 2021 Presentations
      • 2020 Presentations
      • 2019 Presentations
      • 2018 Presentations
      • 2017 Presentations
      • 2016 Presentations
      • 2015 Presentations
      • 2014 Presentations
      • 2013 Presentations
      • 2012 Presentations
      • 2011 Presentations
    • Postcards
    • Events
  • About Us
    • The Foundation
    • People
    • Policies
      • Data, Reagents, and Biomaterials Sharing Policy
      • Publication Policy
      • Reimbursement of Publication Costs
      • Financial Support for Conferences, Meetings, or Workshops
      • Academic Overhead
      • Academic Salary Limits
      • Leave of Absence Policy
      • Eligible Personnel
  • Preclinical research
  • Scientific Publications
  • Community Resources
    • Materials
      • Research tools & reagents
      • Mouse Models
      • Clinical biorepository
    • Data sharing & infomatics
      • Preclinical informatics: HDinHD
    • Funding & partnerships
      • Academic Proposals
      • External Partnership Proposals
    • HD expertise & guidance
      • Independent Statistical Standing Committee
      • Clinical outcomes: Rating scales
      • Field guide to HD mouse models
  • News & Video
    • News
    • HD Therapeutics Conference
      • 2023 Presentations
      • 2022 Presentations
      • 2021 Presentations
      • 2020 Presentations
      • 2019 Presentations
      • 2018 Presentations
      • 2017 Presentations
      • 2016 Presentations
      • 2015 Presentations
      • 2014 Presentations
      • 2013 Presentations
      • 2012 Presentations
      • 2011 Presentations
    • Postcards
    • Events
  • About Us
    • The Foundation
    • People
    • Policies
      • Data, Reagents, and Biomaterials Sharing Policy
      • Publication Policy
      • Reimbursement of Publication Costs
      • Financial Support for Conferences, Meetings, or Workshops
      • Academic Overhead
      • Academic Salary Limits
      • Leave of Absence Policy
      • Eligible Personnel

August 3, 2018

PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease

European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options

RG6042 has the potential to be the first therapy targeting the underlying cause of Huntington’s disease, a fatal neurodegenerative rare disease

Third PRIME designation for a Roche medicine

Basel, 3 August 2018 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company’s investigational medicine RG6042 (formerly known as IONIS-HTTRx) for the treatment of people with Huntington’s disease (HD). RG6042 has demonstrated its ability to reduce the toxic mutant huntingtin protein (mHTT), which is believed to be the underlying cause of HD, in a Phase I/IIa study.[1] PRIME is a designation implemented by the EMA to support data generation and development plans for promising medicines, providing a pathway for accelerated evaluation by the agency, and thus potentially enable them to reach patients earlier.[2]

“We are very pleased that the European Medicines Agency has granted PRIME designation for RG6042, as there is an urgent medical need to find treatment options for families affected by Huntington’s disease,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “Preliminary data on RG6042 were the first to show that levels of toxic mutant huntingtin protein can be lowered in adults with Huntington’s disease, and we are working closely with the EMA and other health authorities to initiate a global phase III study as soon as possible.”

PRIME designation for RG6042 is primarily based on the data from an exploratory Phase I/IIa trial of RG6042 that demonstrated a significant reduction in mHTT, which breaks down the nerve cells in the brain.[1] The study demonstrated a mean 40% (up to 60%) reduction of the specific HD protein in the cerebrospinal fluid (CSF) of adult patients treated with RG6042 for three months at the two highest doses. Furthermore, levels of mHTT measured in the CSF were still declining in the majority of treated patients (~70%) as of the last measurement in the study.[3] RG6042 was well tolerated in this short initial study.[1] These data were shared at the CHDI 13th Annual HD Therapeutics Conference in March 2018,[3] and updated results were presented at the American Academy of Neurology (AAN) Annual Meeting in April 2018.[4]

Roche will initiate a pivotal phase III study to evaluate RG6042 in a larger patient population to further characterise the safety profile and determine if it can slow the progression of HD in adults.

About RG6042

RG6042 is a second-generation modified antisense oligonucleotide (ASO) designed to reduce the production and levels of mHTT protein by targeting human HTT mRNA.[5] RG6042 is the result of a comprehensive drug discovery programme between Roche and Ionis Pharmaceuticals focused on optimising the potency, specificity and tolerability of an ASO targeting human HTT mRNA. RG6042 is the most advanced compound in clinical development to target toxic mutant huntingtin protein (mHTT), which is believed to be the underlying cause of HD. Treatment with RG6042 has the potential to slow or stop disease progression in all people with HD.[1]

About Huntington’s disease

Huntington’s disease is a rare genetic, progressive condition that causes the nerve cells in the brain to break down, which severely affects a person’s everyday functions such as mobility and thinking.[6] It has a devastating impact on people living with the disease, and the hereditary nature of HD means it profoundly affects entire families.[6] As the disease progresses, people with HD may develop personality changes, difficulty walking and swallowing, as well as having a significant cognitive impact.[6] Survival ranges from approximately 10-20 years following motor onset of the disease.[6]

There is no known cure for HD and no approved therapies that treat the underlying cause. The estimates for the number of people affected by Huntington’s vary between geographic regions. Huntington’s disease is the most common monogenic neurological disorder in the developed world, with an estimated prevalence of ~3.5–7/100,000 in North America, Western Europe, and Australia.[7]

About Roche in neuroscience

Neuroscience is a major focus of research and development at Roche. The company’s goal is to develop treatment options based on the biology of the nervous system to help improve the lives of people with chronic and potentially devastating diseases. Roche has more than a dozen investigational medicines in clinical development for diseases that include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, Parkinson’s disease, Huntington’s disease and autism spectrum disorder.

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References

[1] Ionis Pharmaceuticals. 2018. Press release: IONIS-HTT Rx (RG6042) top-line data demonstrate significant reductions of disease- causing mutant Huntingtin protein in people with Huntington’s disease. [Internet; cited 2018 July]. Available from: http://ir.ionispharma.com/node/23401/pdf

[2] European Medicines Agency. PRIME Designation. [Internet; cited 2018 July]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000660.jsp&mid=WC0b01ac05809f8439.

[3] CHDI 13th Annual HD Therapeutics Conference 2018. Press Release: Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington’s Disease. [Internet; cited 2018 July]. Available from: https://chdifoundation.org/ionis-pharmaceuticals-licenses-ionis-htt-rx-to-partner-following-successful-phase-12a-study-in-patients-with-huntingtons-disease/.  (Data on file)

[4] Ionis Pharmaceuticals. 2018. Press release: New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington’s Disease. [Internet; cited 2018 July]. Available from: http://ir.ionispharma.com/node/23661/pdf.

[5] Leavitt B, Tabrizi S, Kordasiewicz H et al. Discovery and early clinical development of ISIS-HTTRx, the first HTT-lowering drug to be tested in patients with Huntington’s disease (PL01.002). Neurology 2016;86(Suppl. 16):PL01.002. [Internet; cited 2018 July]. Available from: http://n.neurology.org/content/86/16_Supplement/PL01.002.

[6] NHS Choices. Huntington’s disease: Overview. [Internet; cited 2018 July]. Available from:  https://www.nhs.uk/conditions/huntingtons-disease/.

[7] Rawlins M, et al. The Prevalence of Huntington’s Disease. Neuroepidemiology 2016;46:144-153.

Post navigation

← Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington’s disease PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington’s Disease →
Connect with CHDI
Provide Feedback on this Page

Send Feedback

We appreciate any comments or questions on this page—our goal is to make this concise and helpful.

Join Our Mailing List
Terms of Use
Privacy Policy
Creative Commons License
Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution 3.0 Unported License.
×

Join Our Mailing List

Receive spam-free updates from the Huntington's disease research community.
×

Terms of Use

  • These Terms of Use apply to your use of CHDI Foundation.org, all its sub-domains and all associated services including, but not limited to, e-mail received from CHDIFoundation.org, any of our computer systems, databases or networks connected to CHDIFoundation.org and all its sub-domains (collectively, the "Website"). The Website is being made available for your use by CHDI Foundation, Inc.

    If you browse or otherwise use the Website, you accept these Terms of Use. We reserve the right to modify these Terms of Use at any time by posting such change here. Your continued use of the Website after such modification is made constitutes your acceptance of, and agreement to be bound by, the Terms of Use as modified. If you do not agree with these Terms of Use, please do not access or use the Website.

    Limitations on Use
    We reserve the right, in our sole discretion, without any obligation or notice requirement, to suspend or deny your access to the Website for any reason, including for scheduled or unscheduled maintenance, upgrades, improvements or corrections.

    You may not attempt to gain unauthorized access to the Website, through hacking, password mining or any other means to circumvent the Website's security procedures. You may not use the Website in any manner that could damage, disable, overburden or impair the Website or any service provided through the Website, or interfere with any other user's use and enjoyment of the Website or any service provided through the Website. You may not make use of the Website or any service provided through the Website to forge e-mail headers or send bulk unsolicited e-mail messages.

    Privacy Policy
    These Terms of Use include our Privacy Policy, which describes how we use your personal information.

    Accuracy of Content
    Any content we provide or post on the Website may contain errors or inaccuracies, including both typographical and substantive errors. We reserve the right, in our sole discretion and for any reason, without any obligation or notice requirement, to discontinue, change, improve or correct the content we provide or post on the Website. Any dated content we provide or post on the Website is published as of its date only and we have no responsibility to update or amend any such content.

    It is your sole responsibility to evaluate the accuracy, completeness or usefulness of any content provided or posted on the Website.

    Links to Other Websites
    These Terms of Use apply only to the Website. We provide links to other websites, but we do not control the content on those websites or their practices. We are not responsible for other websites' content, information collection practices or use of any information they collect. Links to other websites do not constitute an endorsement by us of those websites or their content, owners or posters.

    Your Use of Content Contained on the Website
    The entire Website is copyrighted. Certain content, such as articles, you may find within the Website may also be separately copyrighted by us or by others.

    Except where otherwise expressly noted or contemplated, all content provided or posted on the Website is being made available to you for the purpose of Huntington's disease related research activities.

    Except where otherwise expressly noted or contemplated, we grant you a license to use any content we have provided or posted on the Website under a Creative Commons Attribution 3.0 License. Certain content we have provided or posted on the Website may also be subject to you agreeing to further terms of use specifically covering such content.

    You acknowledge and agree that the permission granted in this section does not constitute an endorsement by us of you or your use of any such content. Please contact us directly for copyright permissions other than those expressly granted in these Terms of Use.

    Disclaimer of Warranties, Not a Substitute for Medical Advice and Limitation of Liability?
    THE WEBSITE IS PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS. WE AND OUR AFFILIATES AND AGENTS MAKE NO REPRESENTATIONS, WARRANTIES OR CONDITIONS OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR OTHERWISE, AS TO THE OPERATION OF THE WEBSITE, OR THE ACCURACY, TIMELINESS OR COMPLETENESS OF CONTENT OR SERVICES INCLUDED ON THE WEBSITE. YOU EXPRESSLY AGREE THAT YOUR USE OF THE WEBSITE AND ANY CONTENT OR SERVICES INCLUDED ON THE WEBSITE IS AT YOUR SOLE RISK.

    ALL CONTENT INCLUDED ON THE WEBSITE, SUCH AS TEXT, TREATMENTS, DATA, DOSAGES, OUTCOMES, CHARTS, PATIENT PROFILES, GRAPHICS, PHOTOGRAPHS, IMAGES, ADVICE, MESSAGES, FORUM POSTINGS AND ANY OTHER CONTENT PROVIDED ON THE WEBSITE ARE FOR INFORMATIONAL PURPOSES ONLY AND ARE NOT A SUBSTITUTE FOR PROFESSIONAL MEDICAL ADVICE OR TREATMENT. YOU SHOULD ALWAYS SEEK THE ADVICE OF YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROVIDER WITH ANY QUESTIONS YOU MAY HAVE REGARDING YOUR HEALTH. NEVER DISREGARD PROFESSIONAL MEDICAL ADVICE OR DELAY IN SEEKING IT BECAUSE OF SOMETHING YOU HAVE READ ON THIS WEBSITE. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. WE DO NOT RECOMMEND OR ENDORSE ANY SPECIFIC TESTS, PHYSICIANS, PRODUCTS, PROCEDURES, OPINIONS, OR OTHER CONTENT THAT MAY BE MENTIONED ON THE WEBSITE.

    YOU EXPRESSLY AGREE THAT NEITHER WE NOR OUR AFFILIATES AND AGENTS ARE LIABLE FOR ANY DAMAGES OF ANY KIND ARISING OR RESULTING FROM YOUR USE OF THE WEBSITE OR ANY CONTENT OR SERVICES INCLUDED ON THE WEBSITE, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, AND CONSEQUENTIAL DAMAGES.

    Copyright Policy
    We respect the intellectual property of others and we ask users of the Website to do the same. In accordance with the Digital Millennium Copyright Act ("DMCA") and other applicable law, we have adopted a policy of, in appropriate circumstances and at our sole discretion, terminating users of the Website who are deemed to be repeat infringers. We may also, at our sole discretion, limit access to the Website of any user of the Website who infringes any intellectual property rights of others, whether or not there is any repeat infringement.

    Procedure for Notifying Us of Claims of Copyright Infringement
    If you believe that any content provided or posted on the Website infringes upon any copyright which you own or control, or that any link on this Website directs users to another website that contains content or descriptions that infringes upon any copyright which you own or control, you may file a notification of such infringement with us as set forth below. Notifications of claimed copyright infringement must be sent to the attention of: CHDI Foundation, Inc., c/o CHDI Management, 350 Seventh Avenue, Suite 200, New York, NY 10001, Attention: David P. Rankin, Chief Legal Officer.

    Governing Law
    These Terms of Use shall be governed by and construed in accordance with the domestic laws of the State of New York, USA without giving effect to any choice or conflict of law provision or rule (whether of the State of New York, USA or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of New York, USA.

    CHDI Foundation, Inc. – www.CHDIFoundation.org – Terms of Use Revision No. 003 (Effective 11/01/2015)

    Download Terms of Use

  • ×

    Privacy Policy

  • This Privacy Policy applies to your use of CHDIFoundation.org, all its sub-domains and all associated services including, but not limited to, e-mail received from CHDIFoundation.org, any of our computer systems, databases or networks connected to CHDIFoundation.org and all its sub-domains (collectively, the "Website"). The Website is being made available for your use by CHDI Foundation, Inc.

    We are committed to protecting the privacy and security of your visits to the Website. This is our online Privacy Policy. If you have questions about this Privacy Policy, please let us know. If you do not agree with this Privacy Policy, please do not access or use the Website.

    We reserve the right to modify this Privacy Policy at any time by posting such change here. We encourage you to refer back to this page and review this Privacy Policy often for the latest information and the effective date of any modifications. If we decide to change this Privacy Policy, we will post a new policy on the Website and change the revision number and effective date at the bottom. Changes to this Privacy Policy will not apply retroactively. Your continued use of the Website after any such modifications are made constitutes your acknowledgement of, and agreement with, the Privacy Policy, as modified.

    Collection of Information and Use
    If you join our mailing list, we collect some information that can be directly associated with you. We call this information "Personal Information" and it includes your name, title and email address and the name of the company or research institution with which you are affiliated. You may modify your Personal Information at any time by following the update profile/email address links at the end of any email we send you.

    By joining our mailing list, you have granted us permission to use your Personal Information to send you emails ("opt-in") relating to our activities and Huntington's disease related research and information. If you have received an email from us, our records indicate that you joined our mailing list. Because we respect your time and attention, we make every effort to control the frequency of our emails.

    You may revoke the permission you have given us to use your Personal Information to send you emails ("opt-out") by following the instructions set out in our e-mails.

    Anti-Spam
    If you believe you have received unwanted, unsolicited email from us sent via the Website or purporting to be sent via the Website, please forward a copy of that email to info@CHDIFoundation.org.

    Privacy and Sharing of Your Personal Information
    It is our general policy not to make Personal Information available to anyone other than our personnel, website administrators, service providers and agents. We may share your Personal Information with our personnel, website administrators, service providers and agents that carry out certain functions on our behalf, such as website hosting, data processing and order fulfillment. Some of these personnel, website administrators, service providers and agents may be located in jurisdictions (including the United States) that may not have the same or as strict privacy laws as your country of residence. We require that our personnel, website administrators, service providers and agents comply with this Privacy Policy when processing or handling Personal Information on our behalf.

    We will not disclose your Personal Information for purposes other than those described herein without your prior consent except as permitted or required by law. In the event of a sale, amalgamation, re-organization, transfer or financing of some or all of our operations, your Personal Information may be disclosed to an acquiring organization, either as part of due diligence or on completion of the transaction. If Personal Information is disclosed in this context, we will require the acquiring organization to comply with this Privacy Policy in its processing and handling of such Personal Information.

    Security
    We maintain a variety of physical, electronic and procedural safeguards to protect your Personal Information. As mentioned above, it is our general policy to restrict access to Personal Information to our employees and agents.

    The Website may have links to other websites that we do not control. You should know that we have no control over the content, privacy policies or security of any of these websites you elect to visit or interact with. Furthermore, we are not responsible for the content, privacy policies or security of any of these websites you elect to visit or interact with and you should check those policies on such websites.

    Browser Information Collected on the Website

    We log IP addresses, which are the locations of computers or networks on the Internet, and analyze them in order to improve the utility of the Website. We also collect aggregate numbers of page hits in order to track the popularity of certain pages and improve the utility of the Website. We do not gather, request, record, require, collect or track any users' Personal Information through these processes.

    We use cookies on the Website. A "cookie" is a tiny text file that we store on your computer to customize your experience and support some necessary functions. We also use cookies to better understand how users use the Website. Our cookies contain no Personal Information and are neither shared nor revealed to other websites. We do not look for or at other websites' cookies on your computer.

    You also have choices with respect to cookies. By modifying your browser preferences, you can accept all cookies, be notified when a cookie is set, or reject all cookies (for more information on how to block or filter cookies, see http://www.cookiecentral.com/faq). However, if you reject some or all cookies, your experience at the Website may not be complete.

    Use of Web Beacons

    When we send emails to users of the Website, we may include a web beacon to allow us to determine the number of users who open our emails. When you click on a link in an email we have sent to you, we may record this individual response to allow us to customize our offerings to you. Web beacons collect only limited information, such as a cookie identifier, time and date of a page being viewed, and a description of the page on which the Web Beacon resides (the URL).

    Web Beacons can be refused when delivered via email. If you do not wish to receive Web Beacons via email, you will need to disable HTML images or refuse HTML (select Text only) emails via your email software.

    Contacting Us

    You have a right to request access to, and rectification of, your Personal Information by contacting us at info@CHDIFoundation.org. If you have any questions about this privacy policy or our Personal Information practices, you may likewise contact us at info@CHDIFoundation.org.

    CHDI Foundation, Inc. – www.CHDIFoundation.org – Privacy Policy Revision No. 003 (Effective 11/01/2015)

  • Click to read a letter from Robert Pacifici, CHDI CSO, regarding COVID-19